Views of Wall Street’s Leading Experts on AIM ImmunoTech Inc.

AIM ImmunoTech Inc. (AMEX: AIM) stock fell -1.69% on Tuesday to $0.64 against a previous-day closing price of $0.66. With 0.12 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.26 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.6698 whereas the lowest price it dropped to was $0.6400. The 52-week range on AIM shows that it touched its highest point at $1.38 and its lowest point at $0.29 during that stretch. It currently has a 1-year price target of $5.42. Beta for the stock currently stands at -0.35.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AIM was down-trending over the past week, with a drop of -16.23%, but this was up by 84.23% over a month. Three-month performance surged to 13.16% while six-month performance fell -13.39%. The stock lost -24.12% in the past year, while it has gained 106.80% so far this year. A look at the trailing 12-month EPS for AIM yields -0.43 with Next year EPS estimates of -0.43. For the next quarter, that number is -0.12. This implies an EPS growth rate of 10.70% for this year and 0.00% for next year. EPS is expected to grow by 25.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 51.50%.

Float and Shares Shorts:

At present, 48.08 million AIM shares are outstanding with a float of 47.42 million shares on hand for trading. On Dec 29, 2022, short shares totaled 0.55 million, which was 1.13% higher than short shares on Nov 29, 2022. In addition to Mr. Thomas K. Equels Esq., J.D., M.S. as the firm’s Exec. Vice Chairman, CEO & Pres, Mr. Peter W. Rodino III, Esq., J.D. serves as its COO, Exec. Director of Gov.al Relations, Gen. Counsel & Sec.

Institutional Ownership:

Through their ownership of 12.28% of AIM’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 6.33% of AIM, in contrast to 5.68% held by mutual funds. Shares owned by individuals account for 2.14%. As the largest shareholder in AIM with 4.11% of the stake, The Vanguard Group, Inc. holds 1,974,387 shares worth 1,974,387. A second-largest stockholder of AIM, Morgan Stanley & Co. LLC, holds 1,355,000 shares, controlling over 2.82% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in AIM, holding 803,590 shares or 1.67% stake. With a 2.73% stake in AIM, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 1,311,599 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 1.29% of AIM stock, is the second-largest Mutual Fund holder. It holds 620,229 shares valued at 0.19 million. Fidelity Extended Market Index Fu holds 0.56% of the stake in AIM, owning 267,854 shares worth 83570.0.


An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Sep 29, 2022, AIM reported revenue of $30.00k and operating income of -$4.70M. The EBITDA in the recently reported quarter was -$4.36M and diluted EPS was -$0.10.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AIM since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With AIM analysts setting a high price target of $6.75 and a low target of $3.00, the average target price over the next 12 months is $5.42. Based on these targets, AIM could surge 954.69% to reach the target high and rise by 368.75% to reach the target low. Reaching the average price target will result in a growth of 746.88% from current levels.


EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. AIM will report FY 2022 earnings on 02/28/2024. Analysts have provided yearly estimates in a range of -$0.40 being high and -$0.44 being low. For AIM, this leads to a yearly average estimate of -$0.42. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. AIM ImmunoTech Inc. surprised analysts by -$0.04 when it reported -$0.13 EPS against a consensus estimate of -$0.09. The surprise factor in the prior quarter was -$0.03. Based on analyst estimates, the high estimate for the next quarter is -$0.10 and the low estimate is -$0.13. The average estimate for the next quarter is thus -$0.12.

Summary of Insider Activity:

Insiders traded AIM stock several times over the past three months with 1 Buys and 0 Sells. In these transactions, 161,291 shares were bought while 0 shares were sold. The number of buy transactions has increased to 5 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 272,608 while 0 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *